Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 3/20 | 0.43 |
| ▸ | KYNU | Q16719 | 3/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975884 | 0.83 | KDM4E (0.63) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL30852338 | 0.81 | KMO (0.51) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL31520067 | 0.81 | KMO (0.51) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL30852376 | 0.81 | KMO (0.51) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL1305231 | 0.81 | KMO (0.51) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL7415502 | 0.78 | KMO (0.41) | KDM4EHIF1ATDP1KMOSLC1A3 | |
| SCHEMBL24591475 | 0.78 | CA12 (0.47) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL9340027 | 0.78 | KDM4E (0.47) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL1332674 | 0.78 | CA12 (0.47) | KDM4EHIF1ATDP1KMOKYNU | |
| SCHEMBL7416410 | 0.76 | KMO (0.46) | KDM4EHIF1ATDP1KMOSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0518530-B1 | Improvements in or relating to excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |